No Data
No Data
Hong Kong stock market active | CXO concept stocks rebounded in early trading, overseas loosening is expected to drive investment and financing to pick up, and there are frequent policies supporting innovative drugs.
CXO Concept Stocks rebounded in early trading, and as of the time of publication, Joinn Laboratories (06127) rose 10.73%, to HKD 7.33; Genscript Bio (01548) rose 5.19%, to HKD 9.53; Pharmaron (03759) rose 5.13%, to HKD 8.6; Tigermed (03347) rose 4.56%, to HKD 28.65.
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Pharmaron (03759) obtained a total of 19 million shares pledged by Lou Xiaoqiang and Beihai Duotai, and a total of 18.063 million shares were released from pledge.
Pharmaron (03759) announced that the company recently received a notification from the actual controller of the company, Lou Xiaoqiang, and his concerted action party Beihai Duotai Venture Investment Co., Ltd. (hereinafter referred to as “Beihai Duotai”), stating that Lou Xiaoqiang and Beihai Duotai have pledged and released part of the company's shares they hold. The total number of shares pledged this time is 19 million shares, of which Lou Xiaoqiang pledged 10 million shares and Beihai Duotai pledged 9 million shares, accounting for a total of 1.06% of the company's total share capital. The number of shares released from pledge this time is 18.063 million shares, of which Lou Xiaoqiang released the pledge in total.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Hong Kong stock market anomaly | CRO concept stocks collectively rose in the afternoon. The Fed's interest rate hiking cycle is nearing its end, and overseas CXO demand is expected to improve first.
Afternoon rally in CRO concept stocks, as of press time, Tigermed (03347) rose 9.85% to HKD 29.55; Frontage (01521) rose 6.58% to HKD 0.81; Pharmaron (03759) rose 4.72% to HKD 8.65; Asymchem Laboratories (06821) rose 2.47% to HKD 47.65; Wuxi Bio (02269) rose 1.97% to HKD 11.4.
No Data